This document announces a one-day symposium on biomarkers for immuno-oncology therapeutics to be held on October 28, 2016 in Foster City, CA. The symposium will introduce fundamentals, technologies, and applications of biomarkers in research, translational, and clinical development of immune-oncology treatments. Nine speakers from academia and biotech/pharma companies will present on topics such as maximizing anti-PD1 therapy, biomarker strategies for combination immunotherapy, biomarkers for novel checkpoint inhibitors, analysis of the tumor microenvironment, and prediction of tumor response to checkpoint inhibitors. The goal is for participants to learn the latest advancements and network with others in the field.

1. A Member Organization of the Pharmaceutical & BioScience Society, International (PBSS)
Biomarkers for Immuno-Oncology:
Fundamentals, Technologies, and Applications for Biomarkers in Research,
Translational and Clinical Development of Immuno-Oncology Therapeutics
A One-Day Minisymposium
Date: Friday, October 28, 2016; 8:00am - 5:30pm
Speakers: Terri McClanahan (Merck), Rod Prell (Genentech), Michael Angelo (Stanford), Luciana Molinero
(Genentech), Manasi Shah (Second Genome), Adil Daud (UCSF), Jeff Wallin (Genentech), Jakob
Dupont (OncoMed Pharmaceuticals), Selda Samagoklu (Pharmacyclics)
Orgnizer: Wenfeng Xu (Genentech), Jeff Wallin (Genentech), Vinita Gupta (Genentech)
Registration Fee (US$): $195 - Regular; $50 - Academic or Between Jobs
Location: Crowne Plaza, Foster City, CA
Registration: http://www.pbss.org/aspx/eventInfo.aspx?eID=512
Registration deadline: 10/26/2016 or earlier
About the Topic
There has been tremendous progress in the field of immuno-oncology as checkpoint inhibitor therapy has
revolutionized the treatment of many cancers. Biomarkers have played a critical role in understanding
mechanism of action, stratifying patient population, discovering new targets, and guiding clinical
development. This one-day symposium will introduce fundamentals, technologies, and applications for
biomarkers in research, translational, and clinical development of immune-oncology therapeutics with
participation from experts in both academia and biotech/pharma. This is a great opportunity to learn the latest
advancements in these areas and also a chance for participants to network and collaborate.
Agenda:
1. Maximizing the Benefit of Anti-PD1 Therapy - Terri McClanahan (Merck)
2. Biomarker Strategies for Combination Immunotherapy – Jeff Wallin (Genentech)
3. Biomarkers for Novel Immune Checkpoint Inhibitors – Jakob Dupont (OncoMed Pharmaceuticals)
4. Analysis of the tumor microenvironment using high dimensional IHC and multiplexed ion beam
imagining – Michael Angelo (Stanford)
5. Biomarker for Breast Cancer Immunotherapy – Luciana Molinero (Genentech)
6. Microbiome Biomarkers in Colorectal Cancer – Manasi Shah (Second Genome)
7. Safety Biomarker in Pre-clinical Models – Rod Prell (Genentech)
8. Novel T cell biomarkers for response to PD1 and PD1/CTLA4 immunotherapy – Adil Daud (UCSF)
9. Prediction of the tumor response to immune checkpoint inhibitors using neoantigens on tumor
cells – Selda Samagoklu (Pharmacyclics)
PHARMACEUTICAL & BIOSCIENCE SOCIETY - SAN FRANCISCO BAY
SAN FRANCISCO BAY